| Section/topic | Item No | Checklist item                                                                 | Reported on Page Number/Line Number | Reported on Section/Paragraph |
|---------------|---------|---------------------------------------------------------------------------------|-------------------------------------|------------------------------|
| TITLE         |         |                                                                                 |                                     |                              |
| Title         | 1       | Identify the report as a systematic review, meta-analysis, or both.              | Page 1, line 2                      | Title page                   |
| ABSTRACT      |         |                                                                                 |                                     |                              |
| Structured summary | 2     | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | Pages 2–3, lines 40–69 | Abstract                     |
| INTRODUCTION  |         |                                                                                 |                                     |                              |
| Rationale     | 3       | Describe the rationale for the review in the context of what is already known.   | Page 4, lines 95–112                | Background                   |
| Objectives    | 4       | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | Page 4, lines 109–112 | Background                   |
| METHODS       |         |                                                                                 |                                     |                              |
| Protocol and registration | 5     | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | NA; No review protocol was published in advance |                              |
| Eligibility criteria | 6     | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | Page 10, lines 242–255 | Inclusion criteria; Exclusion criteria |
| Description | Page(s) | Pages | Search strategy |
|-------------|---------|-------|-----------------|
| **Information sources** | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | Pages 9–10, lines 227–241 |
| **Search** | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | Page 9, lines 230–234 |
| **Study selection** | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | Pages 9–10, lines 236–242 |
| **Data collection process** | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | Page 10, line 260 |
| **Data items** | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | Page 10, lines 258–260 |
| **Risk of bias in individual studies** | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | NA; Risk of bias assessment is limited to ascertainment of study setting and design |
| **Summary measures** | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | Pages 10–11, lines 264–266 |
| **Synthesis of results** | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I²) for each meta-analysis. | Page 11, lines 267–272 |
| **Risk of bias across studies** | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | NA; Risk of bias assessment is limited to |

| Statistic | Page(s) | Supplementary Table |
|-----------|---------|---------------------|
| **Risk of bias across studies** | 15 | NA; Risk of bias assessment is limited to |
| **Summary measures** | 13 | Pages 10–11, lines 264–266 |
| **Synthesis of results** | 14 | Page 11, lines 267–272 |
| **Data items** | 11 | Page 10, lines 258–260 |
| **Search** | 8 | Page 9, lines 230–234 |
| **Study selection** | 9 | Pages 9–10, lines 236–242 |
| **Data collection process** | 10 | Page 10, line 260 |
| **Information sources** | 7 | Pages 9–10, lines 227–241 |
| Description                                      | Pages                                      | Relevant Sections                           |
|--------------------------------------------------|--------------------------------------------|---------------------------------------------|
| Additional analyses                              | Page 10, lines 262–266                     | Statistical analyses                        |
| Study selection                                  | Page 11, lines 278–282; Page 11, lines 287–288; Page 13, line 322; Page 14, lines 350–351; Page 15, line 375 | Results; Figure 1; Table 1; Supplemental Table |
| Study characteristics                            | NA; Data presented in supplemental Table   | Supplemental Table                          |
| Risk of bias within studies                      | NA; Risk of bias assessment is limited to ascertainment of study setting and design | Supplemental Table                          |
| Results of individual studies                    | Pages 16–17, lines 411–428                 | Comparison of outcomes with different ICS techniques to nonapplication of |
| Section | Page | Description | Notes |
|---------|------|-------------|-------|
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | Pages 16–17, lines 411–428 |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | NA; Risk of bias assessment is limited to ascertainment of study setting and design |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | Page 16, lines 394–410 |
| DISCUSSION | | | |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | Pages 17–19, lines 433–485 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | Pages 20–21, lines 496–524 | Limitations and Strengths |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | Pages 21–22, lines 533–550 | Conclusions |

**FUNDING**

| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | Page 23, lines 583–588 | Acknowledgments; Funding; Disclosures; |

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit: www.prisma-statement.org.
Article information: [http://dx.doi.org/10.21037/atm-20-2931](http://dx.doi.org/10.21037/atm-20-2931)

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.*